- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Featured Articles and Interviews
Jun 17, 2025
Top 4 Small-cap ASX Biotech Stocks of 2025
More Featured Articles and Inverviews
Press Releases
More Press Releases
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its lead neuroprotective peptide candidate, ARG007 improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.